)*+,-.ÿ0123456748ÿ913:;56<:;=6<ÿ>67ÿ?6@<A1B
`>CDC1E4F7C45C1AÿGHII=CJÿ?>,
`
` ÿ

ÿ

ÿÿ

ÿ


`KLMNLOPÿRSTÿUVSW
`Xÿÿ#

#ÿÿ

Xÿ

ÿ

%ÿ ÿXÿÿ

ÿY%
`ÿÿ##Xÿ %ÿ

%ÿ

%Zÿ

ÿ$ÿÿ#

ÿÿ[Y%ÿÿ$ÿ!
`ÿ#Yÿ

%ÿZ#

ÿ

ÿ\]"ÿÿÿ^_# ÿÿ
`

#ÿÿ$$#

#ÿ$ÿ$

%

ÿ

 ÿ#ÿ

$

ÿ

ÿ#

ÿ
`Yÿÿ

ÿÿ`

%ÿ"ÿ

#ÿaabXÿY

ÿ#

Xÿ^ÿ`""ÿ

%ÿ$


`^%Xÿÿ[Y%ÿÿ$ÿ%#Y

ÿ ÿ"ÿcÿ

ÿÿ!ÿÿ$!ÿZ#

X
`ÿY%ÿ^ÿÿ

ÿ$ÿ

ÿd

ÿ

$

"ÿeYÿ!ÿY

%
`$ÿ#

ÿ%Y#

ÿÿ

ÿÿY

%%ÿ$ÿ$ÿ#Xÿ_Yÿ

  

ÿÿ
`#

ÿ^ÿÿ%Y



ÿd"ÿfÿ!ÿ %ÿÿÿÿÿYÿYÿÿÿYÿ% 

 "ÿ
`ghijkhljmkÿlopÿqrslptÿ
`ÿ!^ÿÿ#ÿ

d%ÿ!ÿÿXÿ

%ÿÿÿÿ

  "ÿÿÿ!
`
`ÿ

!ÿÿÿXÿÿuvY#dÿÿcYuÿÿ ^Xÿ %

ÿ#

 
`

Y#

ÿ

ÿ!ÿÿYÿÿ%^"ÿcÿ ÿ %ÿ

dÿÿ#


`$

Xÿ

ÿ

%ÿ%#

ÿ$ÿÿ$"ÿwÿ$

XÿYÿ!ÿ#ÿ$ÿ#


`$

%

ÿÿ^

ÿÿ%%ÿ%#Y

"ÿcÿ!ÿÿYÿÿ#ÿÿ#

ÿ^
`

ÿÿÿ#dÿ^ÿ"ÿ$ÿÿÿÿ

ÿ

ÿ#Xÿÿ!ÿ^ÿ%%"ÿe!ÿ
`
`

ÿZÿ$ÿÿ ÿÿÿ%%ÿ$ÿ



ÿÿ#

ÿ

ÿÿ#d
`^"ÿ
` Yÿ ÿ#

ÿÿ

ÿ
`Y# ÿ!!!"#"  % 
`ÿÿ!ÿ^ÿ

ÿ%ÿ$ÿ$

ÿ%Xÿ^YÿYÿ#

ÿÿ$ÿÿYÿÿ$

%ÿ%
` !!!""# $  %  % 



& ' "
`
`   
`
` (
`
`Mylan Exhibit 1080
`Mylan v. Regeneron, IPR2021-00881
`Page 1
`
`Joining Petitioner: Apotex
`
`

`

`   
`
`"ÿ$ÿ)ÿÿ*)ÿ+

ÿ$ÿ#$#ÿ,ÿ)#ÿÿÿ -,ÿ)ÿ#

ÿ#ÿ$ÿ
` ÿ

ÿ

ÿÿ

ÿ


`ÿ!"ÿ

ÿ )ÿ,ÿ

ÿ -ÿÿ!ÿ!ÿ)ÿ.#)ÿÿ!ÿÿ

ÿ$
`
`/)%"
` )ÿ ÿ0ÿ$ÿ
`)# ÿ!!!"#"  % 
`1234526475ÿ69:ÿ;<=>?ÿÿ
`@ÿÿ

ÿ !

ÿ

).ÿ$ÿ$ÿÿ%ÿ#

ÿ

ÿÿA""ÿ)ÿ$"
`

ÿ#

ÿÿ/)%ÿÿ$ÿ

ÿÿÿÿ!,ÿ) ÿÿ/)


`ÿ%$$ÿ$ÿÿ$ÿA""ÿ#

"ÿÿ
`) ÿÿ

).ÿ$ÿ$ÿ

ÿÿÿÿB

 ,ÿÿ

ÿÿ#

#

%
`!ÿ

ÿÿÿ

%$)ÿ$ÿÿ$ÿÿ %ÿ

$

ÿ%#ÿ%ÿÿ
`#

ÿ.)

ÿ

%ÿ$



#ÿ

"ÿ@ÿ$,ÿ#%ÿ.ÿÿ#)ÿ#ÿ$
`CDDÿ

%ÿ#)ÿB#

ÿ#ÿ$ÿCD(,ÿÿ%ÿ.! ÿÿ
`;<=>12>:
`H9:7ÿI6ÿJK?6ÿL:
`E:?F=4G64<7
`;4M:N
`P

$#ÿ!

ÿ$
`ÿD,ÿ(
` ÿ%ÿ$ÿ 


`

%ÿO
`#)
`(Oÿ%ÿ$ÿ/)
`ÿ --)ÿ
`

%
`C ÿ%ÿ$ÿ$#
`ÿ Q

)ÿ
`ÿ

%
`)ÿ.)

ÿ%
`ÿ'Q)

ÿ
` 


`O ÿ%ÿ$ÿ$#
`ÿ

ÿ 

`ÿ

%
`#%)
`

)ÿBÿRÿÿ

)
`(
`

`ÿD,ÿ(ÿ

%ÿOÿ %ÿÿ

ÿ!ÿ ÿ#ÿ$ÿ

ÿ

$

,ÿ
` !!!""# $  %  % 



& ' "
`
` (
`
`Mylan Exhibit 1080
`Mylan v. Regeneron, IPR2021-00881
`Page 2
`
`Joining Petitioner: Apotex
`
`

`

`1/20/2021
`
`EDGAR:Investors' One-Stop-Shop For CompanyFilings
`
`notably whois buying andselling and at what price. These provide transaction data from
`
`firm executives, including board members,as well as institutional buyers with beneficial
`
`interest. Investors find this information valuable, particularly as it relates to understanding
`
`trading patterns(i.e. a large buy orsell order may explain recent price action of a stock)
`
`or determining if a company takeover may occur (an outsiderincreasesits stake in the
`
`firm).
`
`Forms 10-Q and 10-K provide investors with recent financial reports (income statement,
`
`balance sheet and cashflow data, as well as a report on recent businessactivity). This
`
`information reflects past trends and activity, but is the most accurate andreliable
`
`information investors have to make an investmentdecision. At times, companies need to
`
`make amendments to the Form 10-K. This is accomplished by publishing Form 10K/A.
`
`Form 8-K is used as an interim report, when material non-public information thatfalls
`
`under Regulation Fair Disclosure (Reg FD) needsto be disclosed betweentherelease of
`
`a 10-K or 10-Q; material nonpublic information includes a tender offer, merger and
`
`acquisition/dissolution activity, or bankruptcy. Form 8-K is the only reliable source of
`
`information betweenthe quarterlyfilings.
`
`Form S-1 is required for all companiesthat are filing an initial public offering or additional
`
`stock offering. This form provides investors with an overview of the company, business,
`
`competitive landscape, prior financial data and offering information. Schedule 14A
`
`providesall shareholders with proxy materials, including executive compensation, before
`
`the annual meeting.
`
`The Bottom Line
`
`Prior to the creation of EDGAR,investors haddifficulty gathering pertinent information in
`
`a timely and efficient manner. In addition, some investors had advantagesoverothers
`
`based on the sophistication of their research skills - and their connections in the industry.
`
`With the inception of EDGARandthe standardsthat all companies are required to adhere
`
`to, information is disseminated in a more equitable manner. This meansthat small or
`
`individual investors are no longer at a disadvantage dueto lack of up-to-date information
`
`or data. As the ownerof the system, the SEC hasleveled the playing field and created a
`
`repository that houses the most valuable andreliable information and data available to
`
`investors.
`
`https://www.yahoo.com/lifestyle/tagged/health/edgar-investors-one-stop-shop-170000800.html
`
`   
`
`

*ÿ!ÿÿ*+

ÿ

%ÿ

ÿ

%ÿÿ!ÿ#"ÿ,ÿ %ÿ

#

ÿ%ÿ$
` ÿ

ÿ

ÿÿ

ÿ


`$ÿ-#+ .ÿ

#+%

ÿ*%ÿ*.ÿÿ!ÿÿ

+

ÿ*+ÿ!ÿ*

$#
`

"ÿ

ÿ$

%ÿÿ

$

ÿ +*.ÿ#+ÿÿÿÿÿ+

%

%

`
`%

ÿ

ÿ/""ÿÿ ÿ*+ÿÿÿ%ÿÿ-

ÿ#

ÿ#ÿ#

ÿ$ÿÿ#01
`ÿ%



ÿ$ÿÿ#

ÿ0 ÿÿ##+ÿ/

ÿ+%ÿ

#ÿÿ0ÿ

ÿ
`$1"ÿ 2ÿ

%ÿ 3ÿ %ÿ

ÿ!ÿ#

ÿ$



#ÿÿ/

#ÿ

ÿ.
`*

#ÿÿ

%ÿ#ÿ$!ÿ%.ÿÿ!ÿÿÿÿ

ÿ#

ÿ*+

ÿ# 1"ÿ,
`

$

ÿ$#ÿÿ

%ÿ

%ÿ# .ÿ*+ÿÿÿÿ##+ÿ

%ÿ*
`
`

$

ÿ

ÿ ÿÿ0ÿ

ÿ



ÿ%#

"ÿÿ.ÿ#

ÿ

%ÿ
`
`0ÿ

%

ÿÿÿÿ 3"ÿ,ÿÿ##%ÿ*ÿ+*

ÿÿ 3 "ÿ
`ÿ'3ÿÿ+%ÿÿ

ÿ

ÿ.ÿ!

ÿÿ



+*#ÿ

$

ÿÿ$
`+

%ÿ +

ÿÿ#+ÿ/ ÿ1ÿ

%ÿÿ*ÿ%#%ÿ*!

ÿÿÿ$
`
`ÿ 3ÿÿ 24ÿÿ



+*#ÿ

$

ÿ

#+%ÿÿ

%ÿ$$.ÿ ÿ

%
`#5+

%+

ÿ# .ÿÿ*

0+#"ÿÿ'3ÿÿÿ

ÿ*ÿ+#ÿ$
`
`

$

ÿ*!

ÿÿ5+ÿ$

"
`ÿÿÿ5+%ÿ$ÿÿ#

ÿÿÿ$

ÿ

ÿ

ÿ+*#ÿ$$

ÿÿ%%


`#0ÿ$$

"ÿ,ÿ$ÿ %ÿ

ÿ!ÿ

ÿ  !ÿ$ÿÿ#

.ÿ*+

.
`# ÿ

%#.ÿÿ$



#ÿ%ÿ

%ÿ$$

ÿ

$

"ÿ#%+ÿ)
` %ÿÿ%ÿ!ÿ-ÿ.ÿ

#+%

ÿ-#+ ÿ#



.ÿ*$
`ÿ

+ÿ

"
`678ÿ:;<<;=ÿ>?@8ÿ
`Aÿÿÿ#

ÿ$ÿ.ÿ

ÿ%ÿ%$$#+ÿ 

ÿ



ÿ

$

ÿ

`
`ÿÿ

%ÿ$$#

ÿ

"ÿ

ÿ%%

.ÿÿ

ÿ%ÿ% 

 ÿ ÿ
`*%ÿ

ÿÿ#

ÿ$ÿÿ#ÿ0ÿÿ

%ÿÿ#

#

ÿ

ÿÿ

%+"
`Bÿÿ

#

ÿ$ÿÿ

%ÿÿ

%%ÿÿÿ#

ÿÿ5+%ÿÿ%
`.ÿ

$

ÿÿ%

%ÿ

ÿÿÿ5+*ÿ

"ÿ,ÿ

ÿÿÿ
`

% %+ÿ

ÿÿ

ÿ

ÿÿÿ%% 

 ÿ%+ÿÿ#0ÿ$ÿ+%ÿ

$

`ÿ%"ÿÿÿ!

ÿ$ÿÿ.ÿÿÿÿ %ÿÿ

ÿ$%ÿ

%ÿ#%ÿ
`ÿÿ+ÿÿÿ +*ÿ

%ÿ*ÿ

$

ÿ

%ÿ%ÿ *ÿ
`

"
` !!!""# $  %  % 



& ' "
`
`3/4
`
`( )
`
`Mylan Exhibit 1080
`Mylan v. Regeneron, IPR2021-00881
`Page 3
`Joining Petitioner: Apotex
`
`Mylan Exhibit 1080
`Mylan v. Regeneron, IPR2021-00881
`Page 3
`
`Joining Petitioner: Apotex
`
`

`

`1/20/2021
`
`   
`
`EDGAR:Investors' One-Stop-Shop For CompanyFilings
`
` ÿ

ÿ

ÿÿ

ÿ


`
`https://www.yahoo.com/lifestyle/tagged/health/edgar-investors-one-stop-shop-170000800.html
`
` !!!""# $  %  % 



& ' "
`
`4/4
`
`( (
`
`Mylan Exhibit 1080
`Mylan v. Regeneron, IPR2021-00881
`Page 4
`Joining Petitioner: Apotex
`
`Mylan Exhibit 1080
`Mylan v. Regeneron, IPR2021-00881
`Page 4
`
`Joining Petitioner: Apotex
`
`